FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1360-1361 September 23, 2004 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Olsen, N. J. Related Article by O'Dell, J. R. PubMed Citation

To the Editor: The data reported by O'Dell (June 17 issue)¹ and by Olsen and Stein (May 20 issue)² on biologic drugs for the treatment of rheumatoid arthritis reveal many points of uncertainty. First, the number of randomized trials that have compared new biologic agents plus methotrexate with methotrexate alone is small — a single, unreplicated trial of infliximab and adalimumab and two trials of etanercept. (The latest trial is very recent³ and is not mentioned by Olsen and Stein.) In addition, the number of patients who were enrolled in these trials is small (83 in the infliximab group, 67 . . . [Full Text of this Article]

Related Letters:

New Drugs for Rheumatoid Arthritis
Messori A., Santarlasci B., Vaiani M.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:937-938, Aug 26, 2004. Correspondence

This article has been cited by other articles:

• Roberts, L. J., Kalil, A. C., Messori, A., Santarlasci, B., Vaiani, M. (2004). New Drugs for Rheumatoid Arthritis. NEJM 351: 2659-2661 [Full Text]